R&D Pipeline

R&D Pipeline Pipeline (2021-2030)

Pipeline (2021-2030)

Oncology - Gene & Nucleic acids (31)

Modality Indication Targets Stage Company Project No. Detail
1 Development of CD19-Targeted CAR-X Combination Therapy Candidates for Solid Tumors
Gene & Nucleic acids TNBC CD19 Candidate artiCure RS-2026-25503880
2 Development of a Next-Generation Trop2-Targeted Aptamer–Drug Conjugate (ApDC) for Pancreatic Cancer and Solid Tumors
Gene & Nucleic acids Pancreatic cancer, Trop2-positive solid tumor Trop2 Lead APTAMER SCIENCES, Inc. RS-2026-25502769
3 Development of mRNA immuno-oncology therapeutic candidates leveraging an AI-based tumor-targeted fusion cytokine design platform
Gene & Nucleic acids HNSCC **** Candidate CHA Vaccine Institute RS-2026-25501908
4 Development of a Lead Candidate for an Antigen-Presenting Cell-Based Cancer Immunotherapeutic Vaccine Targeting HPV types 31/33/45/52/58
Gene & Nucleic acids HPV 31/33/45/52/58 positive Cervical Cancer or Head and Neck Squamous Cell Carcinoma (HNSCC) HPV 31/33/45/52/58 E6, E7 protein Lead Cellid Co., Ltd. RS-2026-25501687
5 A Phase I study of GM103 administered via intratumoral injection in patients with locally advanced, unresectable, refractory and/or metastatic solid tumors.
Gene & Nucleic acids Ovarian Cancer, Breast Cancer (TNBC) Locally advanced, unresectable, refractory and/or metastatic solid tumors Phase 1 GeneMedicine Co., Ltd. RS-2026-25501678
6 Development of mRNA/LNP-Based Bio-PROTAC Platform Targeting pan-RAS for Lung Cancer Therapy
Gene & Nucleic acids AML/ALL CDK6 Hit Korea Institute of Science and Technology RS-2025-25452986
7 Preclinical Development of an Aptamer-Based Anti-Cancer Drug Targeting ALCAM
Gene & Nucleic acids Ovarian cancer ALCAM (CD166) Candidate HiCellTech Inc. RS-2025-02223684
8 Development of In vivo CAR T using T cell specific Lentivirus
Gene & Nucleic acids Cancer/Immune disease T cell Hit Korea Research Institute of Chemical Technology RS-2025-02223194
9 Development of novel neoadjuvant therapy for triple negative breast cancer (TNBC)
Gene & Nucleic acids Solid cancer Type I interferon Candidate NA Vaccine Institute RS-2025-02213626
10 EGFR-Targeted p53 mRNA-Based Head and Neck Cancer Therapy
Gene & Nucleic acids EGFR (+) Head and Neck cancer p53 Hit Sungkyunkwan University(Research Business Foundation) RS-2025-02213480
11 Phase 1 clinical trial for trans-splicing ribozyme-based RNA editing therapeutics for glioblastoma
Gene & Nucleic acids GBM hTERT mRNA Phase 1 Rznomics Inc. RS-2025-02213273
12 Development of novel drug for anticancer RNA therapy using POC, which is effective in converting cold tumors into hot tumors
Gene & Nucleic acids Pancreatic cancer, SCC(Squamous cell carcinoma), Lung cancer CHI3L1 Lead Autotelic Bio Inc. RS-2025-02213057
13 Development of Lead Compound of Personalized Circular mRNA Therapeutic Cancer Vaccine for the treatment of triple-negative breast cancer ONCOLOGY
Gene & Nucleic acids TNBC Tumor specific neoantigens predicted from deep learning platform technology Lead PENTAMEDIX CO., LTD. RS-2024-00443388
14 Non-clinical Development of gene therapy drug candidates based on oncospreading retroviral vectors
Gene & Nucleic acids Glioblastoma TK & CD genes Preclinical [a:rtiCure] RS-2024-00338747
15 Derivation of new modality ‘Next Generation TPD’ leading materials targeting new target SOX2
Gene & Nucleic acids NSCLC, SCLC SOX2 Lead EPD Biotherapeutics Inc. RS-2024-00337873
16 Development of Innovative Gene Therapy Candidate for Hepatocellular Carcinoma Targeting High-Risk Dual-Specific Protein Phosphatase
Gene & Nucleic acids Hepatocellular Carcinoma CR-P1 Lead CUROGEN Technology RS-2024-00337392
17 Study on the deriving of oHSV-1 candidate for an immunotherapeutic targeting to the ovarian cancer
Gene & Nucleic acids Ovarian cancer Epithelial Cell Adhesion Molecule (EpCAM) Candidate Gencellmed Inc. RS-2024-00332252
18 Development of Lead compound of personalized therapeutic mRNA cancer vaccine by predicting the binding of tumor.reactive T cells and neoantigens
Gene & Nucleic acids Solid Tumor Tumor specific neoantigens predicted by a GENINUS platform based on binding affinity between TCR an Hit GENINUS INC. RS-2023-00284167
19 Development of siRNA therapeutics to target KRAS/G12D.mutant pancreatic cancer
Gene & Nucleic acids Pancreatic cancer KRAS/G12D Candidate Exollence Co., Ltd. RS-2023-00282594
20 Development of mRNA.encoded NK cell engager for the treatment of relapsed/refractory B cell lymphoma
Gene & Nucleic acids B cell lymphoma NK cell Hit De novo Biotherapeutics RS-2023-00258675
21 Candidate selection of a first.in.class RNA therapeuticfor the treatment of BRAF mutant pediatric brain tumors
Gene & Nucleic acids Pediatric brain tumor BRAF Candidate Sovargen RS-2023-00258484
22 Development of a gene therapy for ovarian cancer using bispecific shRNA and antibody escaping oncolytic adenovirus
Gene & Nucleic acids Ovarian cancer c-Myc, BCL2 Lead Curigin Co., Ltd. RS-2023-00219308
23 Non-clinical study of NRT-YHD-001 as macrophage immune check point blocker in liver cancer
Gene & Nucleic acids Liver cancer let-7i-5p miRNA Preclinical NEORNAT Inc. RS-2023-00217374
24 A study on the leading optimization for cancer immunotherapy of regulatory T cell suppression/depletion mechanism using CD25-ApDC (CD25 aptamer-drug-conjugate)
Gene & Nucleic acids Solid Tumor CD25 Lead APTAMER Sciences RS-2022-00166270
25 Development of an implantable anticancer drug for prevention of local tumor recurrence and eradication of existing metastases after tumor resection of triple-negative breast cancer(TNBC)
Gene & Nucleic acids TNBC Nucleolin Lead Interoligo HN22C0585
26 Development of ALCAM aptamer-based ApDC anticancer drug
Gene & Nucleic acids Ovary cancer ALCAM Hit HiCELL Tech HN22C0558
27 ARTI 101 : Oncospreading antitumor retroviral vectors
Gene & Nucleic acids Glioblastoma Cytosine Deaminase Candidate ArtiCure HN22C0469
28 Development of gene therapy for NMIBC using bispecific RNAi
Gene & Nucleic acids Bladder Cancer, Head And Neck Cancer, Pancreatic Cancer mTOR, STAT3 Preclinical Curigin HN22C0365
29 Preclinical Development of LEM-S403 Targeting Tumor Microenvironment Immune Modulation of Immune Checkpoint Inhibitor Non-Responsive Solid Tumor
Gene & Nucleic acids Solid Tumor IDO1 Preclinical Lemonex Inc. HN22C0262
30 Establishment of leading compounds to overcome tumor heterogeneity and anticancer drug resistance of pancreatic cancer and liver cancer by using oncolytic adenovirus/mesenchymal stem cell complex capable of both enhanced tumor targeting and virus replication
Gene & Nucleic acids Pancreatic cancer, Liver cancer TGFβ1, HSP27 Lead Yonsei University HN21C0960
31 GCM-101: Development of cancer-immunotherapy with oncolytic herpes simplex virus (oHSV) in ovarian cancer
Gene & Nucleic acids Ovary cancer EpCAM Lead GenCellMed HN21C0935
BACK